These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 18212797)

  • 1. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing opioid addiction with buprenorphine.
    Donaher PA; Welsh C
    Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
    Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
    Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of addictions.
    Kreek MJ; LaForge KS; Butelman E
    Nat Rev Drug Discov; 2002 Sep; 1(9):710-26. PubMed ID: 12209151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological treatment of substance dependence from a neuroscientific perspective (I): opiates and cocaine].
    Haro G; Cervera G; Martínez-Raga J; Pérez-Gálvez B; Fernández-Garcés M; Sanjuan J
    Actas Esp Psiquiatr; 2003; 31(4):205-19. PubMed ID: 12838444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
    Arfken CL; Johanson CE; di Menza S; Schuster CR
    J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
    Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helping 'them': our role in recovery from opioid dependence.
    Loxterkamp D
    Ann Fam Med; 2006; 4(2):168-71. PubMed ID: 16569721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
    Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
    J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].
    Radomska M; Pach J; Chrostek Maj J
    Przegl Lek; 2001; 58(4):351-3. PubMed ID: 11450367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine: effective treatment of opioid addiction starts in the office.
    Fiellin DA
    Am Fam Physician; 2006 May; 73(9):1513-4. PubMed ID: 16719242
    [No Abstract]   [Full Text] [Related]  

  • 20. Buprenorphine: a primer for emergency physicians.
    Sporer KA
    Ann Emerg Med; 2004 May; 43(5):580-4. PubMed ID: 15111917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.